Workflow
TSZY(002872)
icon
Search documents
ST天圣(002872) - 关于为全资子公司提供担保的进展公告
2025-09-19 11:31
证券代码:002872 证券简称:ST 天圣 公告编号:2025-059 天圣制药集团股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 天圣制药集团股份有限公司(以下简称"公司")于 2025 年 8 月 26 日召开 的第六届董事会第十三次会议审议通过了《关于为全资子公司提供担保的议案》。 同意公司为全资子公司湖北天圣药业有限公司(以下简称"湖北天圣")向银行 申请授信提供担保事项,董事会授权公司经营层在担保额度范围内负责本次担保 相关的协议及文件的签署;在授信额度内,全资子公司向银行申请的具体贷款金 额以银行实际审批的最终结果为准,具体担保金额及保证期间按实际签订合同约 定 执 行 。 具 体 内 容 详 见 公 司 于 2025 年 8 月 28 日 刊 载 于 巨 潮 资 讯 网 (http://www.cninfo.com.cn)上的《关于为全资子公司提供担保的公告》(公告 编号:2025-051)。 二、本次担保的进展情况 近日,湖北天圣与湖北郧县农村商业银行股份有限公司(简称"郧县 ...
ST天圣(002872) - 关于参加重庆辖区2025年投资者网上集体接待日暨半年度业绩说明会活动的公告
2025-09-19 11:31
关于参加重庆辖区 2025 年投资者网上集体接待日 暨半年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有 虚假记载、误导性陈述或重大遗漏。 证券代码:002872 证券简称:ST 天圣 公告编号:2025-060 天圣制药集团股份有限公司 本次活动将于 2025 年 9 月 25 日(星期四)下午 15:00-17:00 举行,投资者 可以登录"全景路演"平台(http://rs.p5w.net)进入公司互动平台参与交流。 为进一步做好投资者关系管理工作,加强与投资者的沟通交流,天圣制药 集团股份有限公司(以下简称"公司")将参加由重庆证监局指导、重庆上市 公司协会联合深圳市全景网络有限公司举办的"重庆辖区上市公司 2025 年投资 者网上集体接待日暨半年度业绩说明会活动"(以下简称"本次活动")。 2025 年 9 月 19 日 届时,公司相关董事及高级管理人员将参加本次活动,并通过网络在线交 流形式,就投资者所关心的问题,与投资者进行"一对多"形式的在线交流, 欢迎广大投资者积极参与。 特此公告。 天圣制药集团股份有限公司董事会 ...
亿元利润竟是“画”出来的 ST天圣账外资金池造假链条曝光
Xin Lang Zheng Quan· 2025-09-19 09:17
另一家关联方重庆吾想装饰工程有限公司(吾想装饰)及其曾用名重庆吾想科技有限公司,以及重庆新 合邦建筑工程有限公司(新合邦建筑),不仅与ST天圣存在大量资金往来,其工商登记信息更是疑点 重重:吾想装饰与新合邦建筑曾使用与ST天圣2017年工商年报完全一致的联系电话,邮箱和地址也高 度重合。泰泓公司的联系电话,则与实控人刘群控制的其他空壳公司如出一辙。 然而,面对如此明显的关联痕迹,ST天圣选择了系统性隐瞒。2017年和2018年,公司未披露的关联交 易金额分别达到惊人的4.81亿元和4863.11万元,导致其年报存在重大遗漏。 一纸来自重庆证监局的《行政处罚事先告知书》,犹如一记重锤,砸向上市仅六年的ST天圣(维权) (002872.SZ),彻底揭开了其精心编织、持续两年的财务造假网络。这家医药企业利用隐秘的关联方 构筑账外资金池,两年间虚增利润高达1.21亿元,其手法之大胆、关联痕迹之明显,令人咋舌,更令其 背后的中介机构责任备受拷问。 隐秘资金池:工程款与采购款的"乾坤大挪移" 监管调查揭示,ST天圣的造假核心在于一套"组合拳"。一方面,公司通过实控人刘群实际控制的重庆 泰泓建筑工程有限公司(泰泓公司)套取 ...
天圣制药信披违规遭警告、罚款 股票被叠加“其他风险警示”
Xin Jing Bao· 2025-09-16 11:21
Core Viewpoint - Tian Sheng Pharmaceutical Group Co., Ltd. (referred to as "Tian Sheng Pharmaceutical") has been penalized by the China Securities Regulatory Commission (CSRC) for inflating profits and failing to disclose related party transactions in its annual reports, resulting in a total fine of 4.99 million yuan for the company and 22 individuals, including the controlling shareholder Liu Qun [2][5]. Group 1: Financial Misconduct - Tian Sheng Pharmaceutical inflated its total profit by 175 million yuan and 47.9 million yuan in the 2017 and 2018 annual reports, respectively, through the use of off-the-books funds [3]. - The company also inflated its procurement costs for traditional Chinese medicine, resulting in a profit reduction of 82.58 million yuan and 19.09 million yuan for the same years, leading to a net profit inflation of 92.20 million yuan and 28.82 million yuan, which accounted for 30.21% and 20.61% of the reported profits for those years [3][4]. Group 2: Related Party Transactions - Tian Sheng Pharmaceutical failed to disclose related party transactions amounting to 481 million yuan and 48.63 million yuan for 2017 and 2018, respectively, which represented 15.08% and 1.49% of the net assets at the end of those periods [4]. - The company did not include its subsidiary, Chongqing Taihong Construction Engineering Co., Ltd., in its consolidated financial statements, nor did it disclose transactions with companies controlled by Liu Qun [4]. Group 3: Legal and Financial Consequences - The CSRC has ordered Tian Sheng Pharmaceutical to correct its disclosures and has imposed fines, including 600,000 yuan for the company and 900,000 yuan for Liu Qun [5]. - Tian Sheng Pharmaceutical has reported continuous losses over the past six and a half years, with a cumulative loss of 1.09 billion yuan, and its revenue has been declining since 2018 [6][7]. - The company’s stock has been under risk warnings since June 5, 2019, due to the controlling shareholder's involvement in fund misappropriation, and additional warnings will be implemented starting September 15, 2025, due to false financial disclosures [8].
证监会出手了!这类股要注意了!
摩尔投研精选· 2025-09-15 10:23
Core Viewpoint - The article highlights the recent regulatory actions by the China Securities Regulatory Commission (CSRC) against multiple listed companies for financial fraud, indicating a zero-tolerance approach towards such violations and aiming to enhance market integrity and investor protection [3][4]. Group 1: Market Overview - A-shares experienced a mixed performance with the ChiNext index outperforming the Shanghai Composite Index, while the total trading volume in the Shanghai and Shenzhen markets decreased by 245.8 billion to 2.28 trillion [1]. - Over 3,300 stocks declined, with only 916 stocks rising, indicating significant sector rotation and concentrated market profitability in certain strong sectors [2]. Group 2: Regulatory Actions - The CSRC imposed administrative penalties on several companies, including ST Dongtong and Yili Clean Energy, for financial misconduct, with fines totaling over 2.29 billion for ST Dongtong and 2.1 billion for Yili Clean Energy [3]. - The regulatory stance reflects a commitment to a "zero tolerance" policy for financial fraud, emphasizing the importance of internal governance and compliance among listed companies [4]. Group 3: Investment Opportunities - Three key areas for investment focus include: 1. Sectors benefiting from policy support, such as energy storage, smart driving, and the automotive supply chain [7]. 2. Sectors with high earnings certainty, particularly in consumer goods and pharmaceuticals [8]. 3. Long-term technology themes, including artificial intelligence, semiconductors, and robotics, which remain attractive post-correction [9].
天圣制药被预处罚,股民索赔可期
Xin Lang Cai Jing· 2025-09-15 07:31
Core Viewpoint - Tian Sheng Pharmaceutical Group Co., Ltd. is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for alleged violations related to profit inflation and failure to disclose related party transactions in its 2017 and 2018 annual reports [1][2]. Summary by Sections Allegations and Findings - Tian Sheng Pharmaceutical inflated total profits by CNY 174,783,429.59 in 2017 and CNY 47,908,869.95 in 2018 through improper financial practices [1]. - The company also inflated costs related to traditional Chinese medicine procurement, resulting in a net profit inflation of CNY 92,204,254.47 in 2017 and CNY 28,823,001.51 in 2018, which accounted for 30.21% and 20.61% of the reported profits for those years, respectively [1]. Regulatory Actions - The CSRC's Chongqing Regulatory Bureau has determined that Tian Sheng Pharmaceutical and its actual controller, Liu Qun, violated the Securities Law by failing to disclose related party transactions and inflating profits [2]. - The CSRC plans to impose corrective measures, issue warnings, and impose fines on the company and responsible individuals [2]. Investor Implications - Investors who purchased Tian Sheng Pharmaceutical's securities between April 23, 2018, and January 8, 2025, and sold or held them after January 9, 2025, may be eligible for compensation due to the alleged violations [3]. - Legal representatives are actively seeking to assist affected investors in filing claims for damages resulting from the company's actions [3][4].
9月15日早间重要公告一览
Xi Niu Cai Jing· 2025-09-15 05:03
Group 1 - Dashi Intelligent signed a contract worth 23.86 million yuan for the Xiaomi Wuhan Phase II smart project, providing a comprehensive smart space solution [1] - ST Tian Sheng's subsidiary passed the consistency evaluation for sodium bicarbonate injection, used for treating metabolic acidosis and certain drug poisonings [1] - Yongyue Technology's actual controller Chen Xiang was released on bail due to allegations of information disclosure violations, while the company's operations remain normal [2] Group 2 - Jushen Co. experienced a stock price fluctuation with a cumulative increase of over 20% over three trading days, while also planning to reduce repurchased shares [2][3] - Shanghai Airport reported a 6.9% year-on-year increase in passenger throughput at Pudong International Airport, totaling 7.9471 million passengers in August [3][4] - Jianlong Micro-Nano announced plans for shareholders to reduce up to 3% of company shares due to fund expiration and exit arrangements [5][6] Group 3 - Yunyong Technology's shareholders plan to reduce up to 2.99% of company shares due to personal funding needs [6] - Zitian Tui's stock entered a delisting arrangement period, expected to last 15 trading days [7] - Pruis's shareholders plan to reduce up to 3% of company shares for personal funding needs [9] Group 4 - Dayilong's shareholders plan to reduce up to 3% of company shares for personal financial arrangements [10] - Yihua New Materials' shareholders plan to reduce up to 1% of company shares for personal funding needs [12] - Huibo Yuntong's controlling shareholder's affiliates plan to acquire a controlling stake in Baode Computer [13] Group 5 - Wanda Information's shareholders plan to reduce up to 3% of company shares for operational needs [14] - Jiafa Education's shareholders plan to reduce up to 3% of company shares for personal funding needs [15] - Guangkang Biochemical's shareholders plan to reduce up to 1.8% of company shares for personal funding needs [16] Group 6 - Yingxin Development's shareholders plan to reduce up to 0.67% of company shares due to bankruptcy asset disposal [18] - Weiye Co.'s shareholders plan to reduce a total of up to 2% of company shares [19] - Kelin Electric plans to raise up to 1.5 billion yuan through a private placement to supplement working capital [20]
天圣制药集团股份有限公司 2025年第三次临时股东大会决议公告
Group 1 - The company held its third extraordinary general meeting of shareholders on September 12, 2025, with no resolutions being rejected [1][2][6] - A total of 100 shareholders participated in the meeting, representing 113,225,082 shares, which is 35.6054% of the total voting shares [7] - The meeting approved several resolutions, including amendments to the company's articles of association and governance systems, with significant support from shareholders [11][12][14][16][18][20] Group 2 - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) regarding violations of information disclosure laws, specifically for inflating profits in 2017 and 2018 [24][25] - The inflated profits amounted to 92,204,254.47 yuan in 2017 and 28,823,001.51 yuan in 2018, representing 30.21% and 20.61% of the reported profits for those years, respectively [25][27] - The company and several executives face fines and potential market bans due to their involvement in these violations, with the actual controller facing a lifetime ban from the securities market [31][34] Group 3 - The company's stock will be subject to additional risk warnings starting September 15, 2025, due to the identified violations, although it will not be suspended from trading [38][40] - The company plans to enhance its internal controls and compliance measures to prevent future violations and improve governance [42]
多家公司涉财务造假遭重罚
Di Yi Cai Jing Zi Xun· 2025-09-14 16:10
Core Viewpoint - The China Securities Regulatory Commission (CSRC) has intensified its crackdown on financial fraud among listed companies, imposing significant penalties on multiple firms for financial misconduct, including forced delisting for some [2][5]. Group 1: Penalties and Companies Involved - Multiple companies, including *ST Dongtong, Lieneng 5 (formerly Yili Clean Energy), *ST Guangdao, ST Tiansheng, *ST Xinchao, and *ST Lingda, have been penalized for financial fraud, with *ST Dongtong and Lieneng 5 facing fines exceeding 100 million yuan [2][3]. - *ST Dongtong was fined 229 million yuan for inflating revenue and profits over four consecutive years, with additional penalties for seven responsible individuals totaling 44 million yuan, and the actual controller facing a 10-year market ban [3][5]. - Lieneng 5, which was delisted in July 2023, was fined 210 million yuan for financial fraud and misleading disclosures over an eight-year period, with penalties imposed on 29 responsible personnel totaling approximately 165 million yuan [4][6]. Group 2: Regulatory Environment and Enforcement - The CSRC has adopted a "zero tolerance" approach towards financial fraud, enhancing the enforcement of penalties and ensuring that both companies and their key personnel are held accountable [5][6]. - Over 70 individuals, including executives and board members, have faced penalties in connection with the financial misconduct of their companies, with some receiving lifetime bans from the securities market [5][6]. - The regulatory framework now includes measures for criminal liability, indicating that administrative penalties are only one aspect of the accountability process for financial fraud [6]. Group 3: Implications for the Market - The trend of increasing penalties and the potential for criminal charges are expected to deter financial misconduct and promote better compliance among listed companies [6]. - The ongoing enforcement actions are likely to lead to the removal of "bad actors" from the market, thereby improving overall corporate governance and compliance standards within the industry [6].
晚间公告丨9月14日这些公告有看头
第一财经· 2025-09-14 14:59
Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets released important announcements on September 14, providing insights for investors [3] Major Events - Yushen Co., Ltd. experienced abnormal stock fluctuations, with a cumulative price increase of over 20% in three consecutive trading days. The company plans to reduce its repurchased shares by up to 1% of its total share capital, consistent with its previously disclosed reduction plan [4][5] - Huibo Yuntong announced that its controlling shareholder, Shenhui Jinwu, intends to acquire 22.0875% of Baode Computing's shares, gaining control of the company. The total transaction price is approximately 1.444 billion yuan, with the acquisition expected to optimize Baode's equity structure and governance [5][6] - ST Zitian's stock will resume trading on September 15 and enter a delisting arrangement period of 15 trading days, with the last trading date expected to be October 13 [7] - Yongyue Technology's actual controller, Chen Xiang, has been released on bail due to an investigation related to the disclosure of important information. The company's operations remain normal [8] - ST Tiansheng's sodium bicarbonate injection has passed the consistency evaluation for generic drugs, indicating its clinical applicability for treating metabolic acidosis [9] Shareholding Changes - Jifa Education's shareholder, Deyuan Tai, plans to reduce its stake by up to 3%, equating to 11.9854 million shares [10] - Dayilong's shareholder intends to reduce its stake by up to 3%, amounting to 5.9708 million shares [11] - Pruis's shareholder, Guanyu Zhao Tai, plans to reduce its stake by up to 3%, totaling 2.3701 million shares [13] - Wanda Information's shareholder, Hexie Health, plans to reduce its stake by up to 3%, equating to 43.2189 million shares [14] - Jianlong Micro-Nano's shareholders plan to reduce their combined stake by up to 3%, totaling 3.0018 million shares [15] - Yunrong Technology's shareholder plans to reduce its stake by up to 2.99%, amounting to 1.8 million shares [16] - Guokang Biochemical's shareholders plan to reduce their stake by up to 1.7973%, totaling 1.33 million shares [17] - Yihua New Materials' shareholder plans to reduce its stake by up to 1%, equating to 1.655 million shares [18] - Yingxin Development's shareholder plans to reduce its stake by 0.67%, amounting to 3.9388 million shares [19] Performance Insights - Shanghai Airport reported an increase in passenger throughput for August, with Pudong International Airport reaching 7.9471 million passengers (up 6.9% year-on-year) and Hongqiao International Airport reaching 4.4515 million passengers (up 2.18% year-on-year) [20][21] Major Contracts - Dashi Intelligent signed a contract worth 23.869 million yuan for the Xiaomi Wuhan Phase II smart project, representing 0.75% of the company's audited revenue for 2024 [22]